drugset / Trial / NCT02246894

A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.

NCT02246894

Phase 3 Completed Bio Products Laboratory

Summary

The main objectives of this study are: * to assess Optivate® consumption (IU/kg consumed per month for prophylactic and on-demand therapy and dose at each bleed). * to assess clinical outcome when treating a bleed with Optivate®. * to evaluate Optivate® in terms of clinical tolerance and safety in children under the age of 6 years. . * to assess FVIII inhibitor development during the study.

Timeline

Start
2003-11
Primary completion
2005-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Wilate Protein / enzyme biologic

Indications